Alphatec (ATEC) Q1 2026 Earnings Transcript

Alphatec reported Q1 revenue of $192 million, up 14% year over year, with surgical revenue rising 17% and adjusted EBITDA jumping 97% to $21 million. However, the quarter missed internal targets due to EOS execution issues, with EOS revenue falling to $14 million and full-year EOS guidance cut to $77 million, even as 2026 total revenue guidance was reiterated at $882 million and EBITDA at $134 million. The company also announced a new JPMorgan/TD Cowen-led debt facility that extends maturities to 2031 and should reduce annual interest expense by more than $6 million.

Analysis

The core setup is a classic quality-vs-execution dislocation: the operating engine is compounding faster than the market likely credits, but the capital equipment leg is injecting volatility into the tape. The surgical franchise appears to be moving from simple surgeon acquisition into deeper wallet-share expansion, which matters because that shifts the growth algorithm from linear to multiplicative over a 12-24 month horizon. If that pattern holds, EOS is not just a revenue line item; it becomes a distribution wedge that can lower customer acquisition cost and raise lifetime value per surgeon, which is much harder for slower-moving incumbents to replicate.

The near-term risk is that investors anchor on the revenue miss and underestimate how much of the shortfall is timing, not demand. That said, timing risk in a capital-install business is real because it creates quarter-to-quarter lumpiness that can compress multiple even when underlying demand is intact. The second-order issue is mix: as lower-ASP procedures and international volumes rise, reported revenue per case may remain under pressure even if unit economics improve, which can keep the market skeptical until the mix normalizes in the back half.

From a competitive standpoint, the bigger threat to peers is not EOS hardware itself but the data layer it can create once embedded. If the platform continues to increase post-adoption pull-through, incumbents may be forced to defend accounts with lower pricing or higher service intensity, especially in institutions where workflow integration matters more than device commoditization. The new debt package is also a subtle positive for equity holders: lower interest drag and longer maturity reduce financing overhang, making the path to FCF inflection more visible just as operating leverage is starting to show through.

Contrarian read: the market may be over-discounting the EOS miss and underpricing the durability of surgeon adoption. The more important signal is that management is preserving EBITDA despite resetting revenue expectations, which implies enough gross margin and opex discipline to absorb moderate execution noise. If Q2 confirms the April rebound and EOS installs normalize, the stock can rerate quickly; if not, this remains a multiple-sensitive name where disappointment can persist for several quarters.

Key Decisions for Investors

• Long ATEC into the next 1-2 earnings cycles; downside is mainly multiple compression if EOS timing remains choppy, while upside is a back-half guide raise or stronger FCF conversion as installs normalize.
• Pair trade: long ATEC / short MDT over 3-6 months — ATEC has the cleaner growth acceleration and operating leverage, while MDT is more exposed to slower-moving hospital capex and lower incremental growth.
• For more convex exposure, buy ATEC call spreads 3-6 months out rather than outright calls; the thesis is a re-rating on execution repair, but the path is noisy enough that defined risk is preferable.
• If the stock rallies on a clean Q2 install print, trim 25-30% of the position into strength; the biggest near-term risk is that the market pays you early for a story that still needs one more quarter of proof.
• Avoid shorting here unless EOS deterioration worsens materially; the combination of surgeon adoption, margin leverage, and cheaper debt makes this more dangerous to fade than the headline miss suggests.